Randomized Phase 3 Study Evaluating the Efficacy and the Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patient with Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 07 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Bendamustine; Gemcitabine; Romidepsin
Indications Follicular lymphoma; Peripheral T-cell lymphoma
Focus Therapeutic Use
Acronyms ORACLE

Most Recent Events

05 Mar 2025 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
09 Oct 2024 Planned End Date changed from 1 Jun 2024 to 1 Dec 2024.
26 Jul 2024 This trial has been completed in Denmark, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight